\News\Home
27-10-2020

Introducing new cancer treatments: how reducing time to Market Access dramatically impacts patients’ lives

In most European countries, reimbursement decision-making tends to drag on for months, sadly pushing the patient perspective further and further into the background. If cancer treatments would be available sooner, how many more patients could be treated? What would be the impact on their health and wellbeing? As part of the Time to Patient Initiative, Vintura and ASC Academics performed an impact analysis. Its findings leave no room for interpretation: for cancer patients, every day counts. Discover more about the Time to Patient Initiative >

Our impact analysis applied three hypothetical reimbursement scenarios to real life cases from the past, using two case study therapies in six countries (Sweden, the Netherlands, England, Italy, Poland, Portugal). A three-step health economic model was developed to calculate: the difference in days between the actual reimbursement timelines and the optimised scenario, the number of additional patients that could have been treated and the health gains these treated patients would achieve. Let’s dive in.

Case study therapies: midostaurin and pertuzumab

Aiming to calculate the impact of earlier reimbursement, we included midostaurin for patients with a rare blood cancer and pertuzumab for pre-surgery early breast cancer. The data on European marketing authorisation, the date of Market Access, the number of new patients on the therapy (uptake) per month and health impact were retrieved respectively from EMA, the manufacturer and national or EUnetHTA assessment reports. Information from assessment reports was retrieved from public sources where possible and, when needed, complemented by manufacturers.

Impact of three scenarios

Using this input, for each therapy and country, the impact of three scenarios was calculated, ensuring the time to reimbursement (start of uptake) changed but the number of new patients per month remained equal.

  1. Highly ambitious scenario: reimbursement at the time of the European marketing authorisation; the time to Market Access is as short as possible.
  2. Best practice scenario: all countries ensure Market Access as fast as the fastest country.
  3. Basic scenario: reimbursement no later than 180 days after the European marketing authorisation, in conformity with the EC Transparency Directive.

Immense health gains

Even in the basic scenario, patients would benefit immensely from accelerating the decision-making process.

Vintura and EFPIA_ Every day Counts report_patient_access blog 5.1
Midostaurin
Vintura and EFPIA_ Every day Counts report_patient_access blog 5.2
Pertuzumab
  • If midostaurin had been reimbursed in England and Italy as fast as agreed in the EC Transparency Directive (within 180 days, a condition fulfilled by the Netherlands and Sweden) 369 more patients with AML could have been treated. They could have lived altogether an additional 18.107 months. This would have corresponded to 1.876 months without the disease getting worse.
  • If pertuzumab had been reimbursed in Sweden and England as fast as agreed in the EC Transparency Directive (a condition fulfilled by the Netherlands): 1.083 more patients with early breast cancer could have been treated. They could have lived altogether an additional 6.181 months. This would have corresponded to 4.408 months when adjusted for the quality of life.

Imagine the impact of a more ambitious scenario, where all countries ensure reimbursement as fast as the fastest country or even as soon as a new therapy receives European marketing authorization. These outcomes show: for cancer patients, every single day counts. Let the outcomes serve as a reminder of the urgency of addressing delays wherever we can. As we’re dealing with a systemic issue, it’s our shared responsibility to step over our own shadow. We owe that much to cancer patients.

Let’s discuss

Inspired to share your thoughts? Or would you like to learn more on how to accelerate patient access? We would be delighted to hear from you. Please feel invited to contact Bas Amesz or Christel Jansen.

Share
It gives me a huge energy boost, together with the client and my colleagues, to find the ideal solution.